GLP-1 Usage Statistics 2026

How many med spas offer semaglutide or tirzepatide?

13,819 of the 53,215 US med spas in our directory (26%) offer GLP-1, going by their Google listings and websites.

Med spas offering GLP-1 are listed in 51 of the 51 states (counting Washington, DC).

Florida has the most GLP-1 providers, with 2,011 med spas.

GLP-1 Provider Statistics: every number →

What else do GLP-1 providers offer?

89% of med spas offering GLP-1 also offer Botox.

85% of med spas offering GLP-1 also offer dermal fillers.

78% of med spas offering GLP-1 also offer microneedling.

GLP-1 Provider Statistics: every number →

Who performs GLP-1?

47% of the 6,123 GLP-1 providers that name their clinical team online list a physician (MD or DO).

51% of the 6,123 GLP-1 providers that name their clinical team online list a nurse practitioner.

14% of the 6,123 GLP-1 providers that name their clinical team online list a physician assistant.

GLP-1 Provider Statistics: every number →

What do med spa GLP-1 programs charge?

118 of the 13,468 med spas offering GLP-1 that have a website (0.9%) publish a price for it; most only quote prices at a consultation.

The median published price for semaglutide is $241 per month, across 108 published prices on med spa websites.

The middle half of published semaglutide prices runs from $150 to $300 per month.

GLP-1 Price Statistics: every number →

Who gets GLP-1?

In KFF's Health Tracking Poll fielded Oct 27–Nov 2, 2025, 18% of U.S. adults said they had ever taken a GLP-1 drug (for weight loss or a chronic condition) and 12% (about 1 in 8) said they were currently taking one, up 6 percentage points from May 2024. [1]

In KFF's May 2024 poll (fielded Apr 23–May 1, 2024), 12% of U.S. adults said they had ever taken a GLP-1 drug, including 6% who were currently taking one. [2]

Among U.S. adults who had ever used a GLP-1 (KFF, Oct–Nov 2025), 30% said they took it primarily to lose weight, 38% primarily to treat a chronic condition such as diabetes or heart disease, and 32% for both; overall 5% of all U.S. adults have taken a GLP-1 primarily to lose weight. [1]

GLP-1 Demographics Statistics: every number →

How many GLP-1 procedures are done each year?

Eli Lilly reported full-year 2025 worldwide revenue of $22.97 billion for Mounjaro (tirzepatide for type 2 diabetes), up 99% from $11.54 billion in 2024. [6]

Eli Lilly reported full-year 2025 revenue of $13.54 billion for Zepbound (tirzepatide for obesity; sold under that name in the U.S., Canada and Japan), up 175% from $4.93 billion in 2024; Q4 2025 U.S. Zepbound revenue was $4.2 billion. [6]

Novo Nordisk reported 2025 Wegovy sales of DKK 79.1 billion worldwide (up from DKK 58.2 billion in 2024), of which DKK 51.0 billion came from US Operations; Ozempic sales were DKK 127.1 billion. [7]

Novo Nordisk's 2025 annual report says sales of its obesity-care products rose 26% (31% at constant exchange rates) to DKK 82.3 billion, that the global branded GLP-1 obesity market grew 104% in volume, and that Novo held a 59.6% branded volume share (IQVIA data). [7]

What percentage of GLP-1 users have side effects?

KFF (Oct–Nov 2025): among adults who had used a GLP-1 but stopped, 14% said they stopped because of cost and 13% because of side effects (both shares are of all ever-users). [1]

EMA's safety committee (PRAC) concluded on June 6, 2025 that NAION, an optic-nerve condition that can cause vision loss, is a 'very rare' side effect of semaglutide (Ozempic, Rybelsus, Wegovy), meaning it may affect up to 1 in 10,000 people taking it. [9]

How well does GLP-1 work?

SURMOUNT-1 (Jastreboff et al., NEJM 2022; n=2,539; 72 weeks, with lifestyle counseling): 85%, 89% and 91% of people on tirzepatide 5, 10 and 15 mg lost at least 5% of body weight vs 35% on placebo, and 50% (10 mg) and 57% (15 mg) lost 20% or more vs 3% on placebo. [10]

STEP 1 (Wilding et al., NEJM 2021; 68 weeks, with lifestyle intervention): 69.1% of people on semaglutide 2.4 mg lost at least 10% of body weight vs 12.0% on placebo; 4.5% on semaglutide stopped treatment because of gastrointestinal side effects vs 0.8% on placebo. [11]

In real-world care (Gasoyan et al., Obesity 2025; 7,881 Cleveland Clinic adults without diabetes who started semaglutide or tirzepatide in 2021–2023), mean weight loss at one year was 8.7% — 11.9% for those who stayed on treatment, 6.8% for those who stopped after 3–12 months and 3.6% for those who stopped within 3 months — lower than in the phase 3 trials. [12]

GLP-1 Results Statistics: every number →

How do patients rate GLP-1 providers on Google?

Google reviews of med spas offering GLP-1 average 4.87 stars, across 1,699,696 reviews of 13,139 rated listings.

96% of the Google reviews left for GLP-1 providers are 5-star.

86% of GLP-1 providers with at least 5 reviews hold a 4.8-star rating or better.

GLP-1 Results Statistics: every number →

What published research says

These numbers come from outside sources, not our directory; each one links to its source below.

• KFF (Oct–Nov 2025): current GLP-1 use was highest among adults 50–64 (22%), versus 4% at ages 18–29, 11% at 30–49 and 9% at 65+; women were more likely than men to be current users (15% vs 9%). [1]
• KFF (Oct–Nov 2025): current GLP-1 use was 45% among adults ever diagnosed with diabetes, 29% among those with heart disease, and 23% among those told they were overweight or obese in the past five years; insured adults were far more likely to be current users than uninsured adults (12% vs 4%). [1]
• Where people get GLP-1s (KFF, Oct–Nov 2025): among adults who have ever taken one, 76% got it from their primary care doctor or a specialist, 17% from an online provider or website, and 9% from a medical spa or aesthetic medical center. [1]
• In KFF's May 2024 poll, 79% of adults who had taken a GLP-1 got it (or the prescription) from their primary care doctor or a specialist, 11% from an online provider or website, and 10% from a medical spa or aesthetic medical center. [2]
• KFF (Oct–Nov 2025): 56% of adults who had used GLP-1s said the drugs were difficult to afford (about 1 in 4 'very difficult'), and 27% said they had insurance but paid the full cost themselves. [1]
• Gallup's 2026 National Health and Well-Being Index survey (May 28–June 5, 2026; n=5,065) found 11% of U.S. adults currently take a GLP-1 medication for weight loss, up from 3% in 2024, and 15% have ever used one for weight loss. [3]
• Gallup (2026 survey, n=5,065): among current GLP-1 weight-loss users, 66% use a brand-name product such as Ozempic or Wegovy, 18% use a compounded or 'custom-mixed' version, and 13% are unsure which they use. [3]
• Gallup (2025, n=16,946, first three quarters of 2025) reported 12.4% of U.S. adults taking a GLP-1 specifically for weight loss (15.2% of women, 9.7% of men), up from 5.8% in February 2024; use was 16.2% at ages 40–49, 17.0% at 50–64 and 11.1% at 65+. [4]
• Gallup's self-reported U.S. adult obesity rate fell from a record 39.9% in 2022 to 37.0% in 2025 and 36.8% so far in 2026; Gallup notes self-reported height/weight runs lower than measured (NHANES) estimates and the decline is a correlation with GLP-1 use, not proof of cause. [3]
• CDC/NCHS (NHANES, measured height and weight, August 2021–August 2023): 40.3% of U.S. adults had obesity and 9.4% had severe obesity; obesity was highest at ages 40–59 (46.4%). [5]
• In ASPS's 2025 member survey, 82% of ASPS member plastic surgeons reported consultation requests related to GLP-1 medication use; surgeons most often cited tummy tucks (88%), breast surgery (87%), arm lifts (84%) and facelifts (71%) in GLP-1-related consultations. [8]
• EMA says large epidemiological studies suggest semaglutide in adults with type 2 diabetes is associated with roughly a two-fold increase in NAION risk versus not taking it, which corresponds to about one additional NAION case per 10,000 person-years of treatment (2025 data). [9]

What these numbers can't tell you

• Counts are Google Maps listings we classify as med spas, so they include dermatology and plastic surgery practices that offer med spa treatments and exclude spas without a Google listing.
• A treatment counts when the spa's Google listing or website names it, so a spa with an outdated menu can be over- or under-counted.
• Credentials count only clinicians a spa names with a credential (MD, DO, NP, PA, RN) on its own website, so spas that leave their team off their website are left out of those shares.
• Prices are published prices on med spa websites: we keep each spa's lowest posted price, which often is an introductory or member price, so the typical bill is higher.
• We hold no patient records: every figure describes providers, their listings and their Google reviews, not who gets treated.
• Ratings and review themes are Google's, as shown on each listing on the snapshot date; Google filters some reviews and does not publish how.

Medical disclaimer. MedSpaStandard is for education only and is not medical advice. Talk to a licensed provider about your own health, and check any provider's license with your state board.